E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Relapsing Remitting Multiple Sclerosis (RRMS) |
schubförmige remittierende multiple Sklerose |
|
E.1.1.1 | Medical condition in easily understood language |
Relapsing remitting multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, which progresses in single relapses. |
Schubförmig remittierende Multiple Sklerose (MS) ist eine chronisch-entzündliche Erkrankung des zentralen Nervensystems, welche in einzelnen Schüben verläuft. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10063399 |
E.1.2 | Term | Relapsing-remitting multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluation of changes of the visual sysetm in RRMS patients treated with dimethyl fumarate assessed by RNFL thickness measured by OCT over 36 months |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Written informed consent from patients capable of giving or withholding full informed consent must be obtained before any assessment is performed. 2. Male or female subjects aged 18-64 years. 3. Subjects with a) relapsing remitting MS (RRMS) defined by 2010 revised McDonald (Polman et al., 2011) criteria OR b) early MS (100 patients, reference cohort) a) Patients with diagnosis of RRMS must satisfy the approved therapeutic indication for dimethyl fumarate (DMF) (as per local SmPC) and must have been clinically stable on DMF for at least 4 and up to 16 weeks prior to screening visit b) Patients in the reference cohort must have had a single neurological episode within 60 months before screening. They have to be without immunomodulatory treatment at screening. They must not have a progressive form of MS. Patients for the reference cohort may be evaluated also retrospectively at selected sites if they have given full informed consent. The following data have to be recorded or available for these reference patients: - Demography - Neurological examination / EDSS - OCT - Visual acuity (BCVA)
4. Patients with Expanded Disability Status Scale (EDSS) score of 0-5.5 (including). 5. RNFLT at screening (for RRMS patients) must be at least 84µm and high contrast ETDRS visal acuity >0.5 in at least one eye (OCT has to be confirmed by Central Reading Center). For reference patients criteria have to be fulfilled at time of first documented OCT measurement. |
|
E.4 | Principal exclusion criteria |
1. Patients that are unwilling or unable to comply with study requirements, or are deemed unsuitable for study participation as determined by the Investigator. 2. Patients that have major comorbid conditions that preclude participation in the study, as determined by the Investigator. 3. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG test (urine dipstick). 4. Women of childbearing potential and not using appropriate contraception (per local DMF SmPC) as determined by the Investigator. 5. Patients with known hypersensitivity to the active ingredient in the DMF drug product or to any of the excipients listed in the local DMF SmPC (for the RRMS cohort). 6. Patients with a contraindication to DMF according to SmPC (for the RRMS cohort) 7. Patients with an onset of acute optic neuritis within the last 3 months. 8. Patients with an MS relapse within the last 30 days 9. Concomitant use of drugs that may directly affect retinal structure and function (e.g. chronic systemic corticosteroids). 10. Patients with any ophthalmologic reason for RNFL pathology other than MS, such as: optic neuropathy, active advanced glaucoma, injury of the optic nerve based on the ophthalmologist’s clinical judgment. 11. Patients with evidence of advanced, non-proliferative or proliferative diabetic retinopathy. 12. Patients with presence of retinal conditions associated with edema, subretinal fluid, cysts, etc. 13. Patients with history or presence of severe myopia (> - 6 dpt). 14. Patients who participate in another interventional study. 15. Patients who are institutionalized by court or official order |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Parameters of interest
-Ganglion cell and inner plexiform layer (GCIPL) thickness as measured by OCT at Baseline, months 12, 24, and 36 -Retinal nerve fiber layer thickness (RNFLT) as measured by OCT at Baseline, months 12, 24, and 36 -Optic nerve head volume (ONH-V) as measured by OCT at Baseline, months 12, 24, and 36 -Visual acuity (ETDRS, Landolt and Sloan charts) at Baseline, months 12, 24, and 36 -Visual quality of life (NEI-VFQ-25) at Baseline, months 12, 24, and 36 -EDSS at Baseline and months 12, 24 and 36 -Annual relapse rate (ARR) over 36 months -AEs and SAEs over 36 months -Central visual field as measured by perimetry at Baseline, months 12, 24, and 36 -Inner nuclear layer (INL) thickness as measured by OCT at Screening, Baseline, months 12, 24, and 36 -QoL (PRIMuS) at Baseline, months 12, 24 and 36 -Disability Progression (MSFC) at Baseline, months 12, 24 and 36 -Cognition (SDMT) at Baseline, months 12, 24 and 36 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
EDSS, MSFC, SDMT and Sloan chart measurements |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |